| progesterone / Generic mfg. |
2013-003304-39: Assisted reproduction and the early luteal phase The effect of ovulation induction on the endocrine profile Assisteret reproduktion og den tidlige luteal fase Ovulationsinduktionens påvirkning af den endokrine profil |
|
|
| Ongoing | 4 | 179 | Europe | Lentogest, Crinone, Solution for injection, Vaginal gel, Lentogest | Fertilitycenter Odense, Nordic InfuCare, IBSA | Infertility, particularly the luteal phase during IVF, Infertility, particularly the luteal phase during IVF, Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
2020-004329-21: Reduction of progesterone elevation at trigger in poor responder Bologna’ criteria patients after controlled ovarian stimulation with long acting standard stimulation protocol compared with conventional daily protocol: a single center prospective randomized Fase IV trial Riduzione dell’incidenza di rialzo precoce del progesterone il giorno dell’induzione dell’ovulazione dopo stimolazione ovarica con il protocollo a lunga durata d’azione rispetto al protocollo giornaliero convenzionale nelle pazienti con prevista scarsa risposta ovarica secondo i criteri di Bologna: studio monocentrico, randomizzato, di fase IV |
|
|
| Not yet recruiting | 4 | 110 | Europe | Elonva, Puregon, [Elonva], [Puregon], Solution for injection, ELONVA - 150 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) - 0.5 ML 1 SIRINGA PRERIEMPITA + 1 AGO, PUREGON - 300 UI/0.362 ML SOLUZIONE INIETTABILE 1 CARTUCCIA USO SOTTOCUTANEO | OSPEDALE SAN RAFFAELE, MERCK SHARP & DOHME CORP. | Patient with poor ovarian response Pazienti con ridotta risposta alla stimolazione ovarica controllata, Patient with poor ovarian response Pazienti con ridotta risposta alla stimolazione ovarica controllata, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
| Completed | 4 | 120 | Europe | Double Stimulation (Elonva+rFSH) in luteal /follicular phase, Conventional Stimulation (Elonva+rFSH) in follicular phase | Fundación Santiago Dexeus Font, Merck Sharp & Dohme LLC | Infertility | 01/23 | 05/23 | | |
| Recruiting | 4 | 120 | Europe | rhFSH+rhLH, rhFSH | Fundación Santiago Dexeus Font, Merck, S.L., Spain | Infertility | 08/25 | 11/25 | | |
2016-001590-32: Controlled ovarian stimulation with highly purified menotropin in low-responder patients. Estimulación ovárica controlada con menotropina altamente purificada en pacientes bajas respondedoras |
|
|
| Ongoing | 3 | 64 | Europe | TESTOSTERONA TRANSDERMICA, TRIPTORELINE ACETATE, ORAL CONTRACEPTIVES, PROGESTERONE, Powder and solution for solution for injection, Transdermal gel, Tablet, Capsule, soft, MENOPUR, TESTOSTERONA TRANSDÉRMICA GEL, TRIPTORELINE ACETATE, ORAL CONTRACEPTIVES, PROGESTERONE | Manuel Macía Cortiñas, FERRING PHARMACEUTICALS | PRIMARY INFERTILITY Esterilidad primaria, INFERTILITY Esterilidad, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-004112-10: Study of the effect of an additional administration of Amelgen® 400 mg in women with a low progesterone value on the day of embryo replacement |
|
|
| Not yet recruiting | 3 | 807 | Europe | Vaginal tablet, Amelgen | Ghent University Hospital, Gedeon Richter Pharma GmbH | Patients who undergo artificial vitrified/warmed single blastocyst transfer cycles with low progesterone (defined as <10mcg/l) on day of embryo transfer., Patients with a low progesterone level on the day of embryo transfer during an artificial cycle., Body processes [G] - Reproductive physiologi cal processes [G08] | | | | |
| Active, not recruiting | 3 | 1570 | Europe, Canada, US, RoW | Estetrol oral tablet, Placebo oral tablet, Progesterone oral tablet | Estetra, ICON Clinical Research | Vasomotor Symptoms, Menopausal Symptoms | 02/24 | 02/24 | | |
| Recruiting | 3 | 680 | US | Progesterone-IBSA Injectable Solution, Prolutex, Progesterone Vaginal Gel with Applicator, Crinone, Placebo Vaginal gel with applicator, Placebo injectable solution | IBSA Institut Biochimique SA | Infertility | 09/24 | 03/25 | | |
ANGAS, NCT06091436: To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference |
|
|
| Recruiting | 3 | 176 | RoW | GenSci094, Placebo RecFSH / follitropin alfa, Biological: RecFSH / Follitropin alfa (Days 1 to 7), Placebo GenSci094, RecFSH / Follitropin alfa (Days 8 to hCG), Ganirelix, hCG, Progesterone | Changchun GeneScience Pharmaceutical Co., Ltd., Sixth Affiliated Hospital, Sun Yat-sen University | Infertility | 02/24 | 08/24 | | |
| Completed | 2 | 213 | Europe | Progesterone subcutaneous, Progesterone Vaginal Product | IBSA Institut Biochimique SA | Infertility | 09/22 | 12/22 | | |
| Active, not recruiting | 2 | 150 | Canada | Progesterone Effervescent Vaginal Tablet, Endometrin | Clinique Ovo, Ferring Pharmaceuticals | Fertility Issues, Embryo Implantation, Frozen Embryo Transfer | 09/25 | 06/26 | | |
NCT04445025: Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis |
|
|
| Active, not recruiting | 1 | 30 | US | Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work | Colorado Center for Reproductive Medicine, AbbVie | Infertility, Endometriosis | 09/24 | 12/24 | | |
NCT03924440: Ovulation Double Check (Proov) Verification and Usability Testing |
|
|
| Completed | N/A | 100 | NA | Proov (Ovulation Double Check) Test | MFB Fertility | Ovulation Disorder | 12/21 | 12/22 | | |
NCT04874285: Use of Dietary Supplements in Patients at Risk of Abortion Treated With Progesterone. |
|
|
| Completed | N/A | 63 | Europe | HA | Lo.Li.Pharma s.r.l | Pregnancy, High Risk | 05/22 | 05/23 | | |
KITCHEN, NCT04301518: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs |
|
|
| Active, not recruiting | N/A | 6500 | US | Multimodal intervention strategy | Sera Prognostics, Inc., High Risk Pregnancy Center, Las Vegas, Nevada | Preterm Labor, Preterm Birth | 12/23 | 12/26 | | |
NCT06097559: International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures |
|
|
| Recruiting | N/A | 738 | Europe, US, RoW | Endometrial fluid and biopsy collection | Igenomix | Infertility of Uterine Origin, Implantation Failure | 04/26 | 12/26 | | |